ImmunoKey
- Biotech or pharma, therapeutic R&D
ImmunoKey is a seed-stage UK biotechnology company developing a first-in-class platform technology to unlock the potential of CAR T-cell therapy for solid cancers.
Our pipeline is built around the CARKey™ platform, that enables maximal tumour coverage and reduced antigen escape through multi-antigen targeting, whilst minimising harm to healthy tissues. This is complemented by AmpliT™ and ReviT™, technologies that address T-cell exhaustion and the suppressive tumour microenvironment.
Backed by a leadership team with proven success in cell therapy development, exit, and clinical implementation, ImmunoKey is poised to unlock new possibilities in cancer immunotherapy.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}